Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessio...
Saved in:
| Published in: | PloS one Vol. 15; no. 11; p. e0242630 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Public Library of Science
25.11.2020
Public Library of Science (PLoS) |
| Subjects: | |
| ISSN: | 1932-6203, 1932-6203 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up).
A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28).
The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse.
SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. |
|---|---|
| AbstractList | Purpose To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). Methods A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93[euro] = US$1.10, www.xe.com, 2020/10/28). Results The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. Conclusions SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28). The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93[euro] = US$1.10, www.xe.com, 2020/10/28). The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. Purpose To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). Methods A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28). Results The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. Conclusions SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. Purpose To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up). Methods A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28). Results The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse. Conclusions SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up).PURPOSETo compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up).A 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28).METHODSA 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28).The total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse.RESULTSThe total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse.SCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals.CONCLUSIONSSCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. PurposeTo compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G (SCIg) associated with an interprofessional drug therapy management programme (initial training and follow-up).MethodsA 48-week model-based cost-minimization analysis from a societal perspective was performed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week initially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals, infusion material, transport and losses of productivity for patients. Costs were expressed in Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28).ResultsThe total costs of IVIg were higher than those of SCIg for health insurance and other payers: 114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The results were sensitive to the immunoglobulin doses, as this was the main cost driver. The SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg was, but the additional costs were compensated during the maintenance phase (from week 28). The professional costs associated with the switch were not fully covered by the insurance and were borne by the pharmacist and the nurse.ConclusionsSCIg for CIDP patients reinforced by an interprofessional drug therapy management programme may be a cost-effective and sustainable alternative to IVIg in the Swiss system context. From an economic perspective, this therapy alternative should be more widely supported by healthcare systems and proposed to eligible patients by professionals. |
| Audience | Academic |
| Author | Perraudin, Clémence Vicino, Alex Kuntzer, Thierry Berger, Jérôme Bugnon, Olivier Bourdin, Aline |
| AuthorAffiliation | 2 Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland 4 Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, Switzerland 3 School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland 1 Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland Universita degli Studi di Napoli Federico II, ITALY |
| AuthorAffiliation_xml | – name: 3 School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland – name: 4 Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Lausanne, Switzerland – name: 1 Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland – name: 2 Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV), Lausanne, Switzerland – name: Universita degli Studi di Napoli Federico II, ITALY |
| Author_xml | – sequence: 1 givenname: Clémence orcidid: 0000-0002-3533-2764 surname: Perraudin fullname: Perraudin, Clémence – sequence: 2 givenname: Aline orcidid: 0000-0002-1331-4557 surname: Bourdin fullname: Bourdin, Aline – sequence: 3 givenname: Alex surname: Vicino fullname: Vicino, Alex – sequence: 4 givenname: Thierry surname: Kuntzer fullname: Kuntzer, Thierry – sequence: 5 givenname: Olivier surname: Bugnon fullname: Bugnon, Olivier – sequence: 6 givenname: Jérôme surname: Berger fullname: Berger, Jérôme |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33237959$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk1uLEzEUxwdZcXer30B0QBB9mJrLXPdBKIu6hYUFV30NSSZpUzJJN8mo9Rv4rU3bqXSWRWRgZjj5nf_JuZ0nJ8YakSTPIZhCXMF3K9s7Q_V0Hc1TgHJUYvAoOYMNRlmJAD45-j9Nzr1fAVDguiyfJKcYI1w1RXOW_L6yncgY9aJNfc94H6gRtvep6rre2IW2rNfKpNK6lC-dNYqnykhNu44G6zZpK7qNiAQNyizStdUbI3pn1zQsN2l8K2GCv0hn6e0P5X3KrQ9Zp4zq1K94aE1KYxIbr_zT5LGk2otnw3eSfP344cvlVXZ982l-ObvOeIlQyHBTSYBwg1kOIMNA1JxJ0FCGG0k5Y6wqqlZWSJYAMYZgmdMG1UVNYV6zphJ4krzc66619WSooicoL3Mca9XASMz3RGvpiqyd6qjbEEsV2RmsWxDqguJaEASALASDlYQgb7lkLRMYx7u0Ba8xzaPW-yFazzrR8lgNR_VIdHxi1JIs7HdSlXUN8yIKvBkEnL3rhQ-kU54Lrfd92t27BGWVb2O9uoc-nN1ALWhMIPbSxrh8K0pmZY5qiGAcpUkyfYCKT-y34nHkpIr2kcPbkUNkgvgZFrT3nsxvP_8_e_NtzL4-YpeC6rD0Vvfb2fFj8MVxpf-W-DDrEbjYA9xZ752QhKuwm8GYmtIEArJdrEPRyHaxyLBY0Tm_53zQ_6fbH5m6Kwk |
| CitedBy_id | crossref_primary_10_1007_s10072_024_07640_3 crossref_primary_10_1016_j_japh_2023_06_021 crossref_primary_10_1080_03007995_2024_2351165 crossref_primary_10_3390_cells12192417 crossref_primary_10_1007_s40259_023_00609_2 crossref_primary_10_3390_jcm12062431 crossref_primary_10_57264_cer_2023_0171 crossref_primary_10_1111_tme_12889 crossref_primary_10_1097_NAN_0000000000000581 crossref_primary_10_1002_mus_27356 crossref_primary_10_3389_fneur_2025_1506465 crossref_primary_10_1016_j_sapharm_2023_07_001 crossref_primary_10_1186_s13023_023_02715_4 |
| Cites_doi | 10.1007/s10198-004-0250-5 10.1007/s10072-014-1632-9 10.1097/NAN.0000000000000087 10.1038/s41598-020-64699-6 10.1016/S0140-6736(95)90346-1 10.1007/s10875-006-8905-x 10.2147/PPA.S76139 10.1111/j.1365-2249.2009.04079.x 10.1016/j.jns.2017.04.039 10.1186/1471-2458-6-51 10.1097/NAN.0000000000000240 10.1111/j.1365-3148.2012.01201.x 10.1186/s13063-016-1466-2 10.1016/S1474-4422(17)30378-2 10.1212/NXI.0000000000000590 10.1111/jns.12158 10.1186/s13012-015-0327-9 10.1007/s10875-016-0288-z 10.1002/mus.25409 10.1016/j.childyouth.2013.10.006 10.1111/j.1365-2125.2012.04167.x 10.1016/j.jns.2019.116497 10.1002/brb3.923 10.3111/13696998.2012.716804 10.1177/1756285614563056 10.1007/s10875-012-9720-1 10.1111/j.1529-8027.2012.00444.x |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 Public Library of Science 2020 Perraudin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 Perraudin et al 2020 Perraudin et al |
| Copyright_xml | – notice: COPYRIGHT 2020 Public Library of Science – notice: 2020 Perraudin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 Perraudin et al 2020 Perraudin et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0242630 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Database ProQuest Central Essentials ProQuest : Biological Science Collection journals [unlimited simultaneous users] ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Agricultural Science Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Public Health |
| DocumentTitleAlternate | Home-based subcutaneous immunoglobulin and cost-minimization analysis |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2464362091 oai_doaj_org_article_200f5eb17f104dcfbdbe33b39d5c83a4 PMC7688145 A642812126 33237959 10_1371_journal_pone_0242630 |
| Genre | Journal Article Comparative Study |
| GeographicLocations | Switzerland United States--US |
| GeographicLocations_xml | – name: Switzerland – name: United States--US |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ ALIPV BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c622t-397f02393b401b30e8cbf09ab39facbbb757df72f602bb2164a92858a148b97e3 |
| IEDL.DBID | P5Z |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000593887000057&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Sun Feb 05 03:14:14 EST 2023 Fri Oct 03 12:53:32 EDT 2025 Tue Nov 04 01:54:45 EST 2025 Thu Oct 02 04:13:20 EDT 2025 Tue Oct 07 09:20:59 EDT 2025 Sat Nov 29 13:18:17 EST 2025 Sat Nov 29 10:02:20 EST 2025 Wed Nov 26 09:25:49 EST 2025 Wed Nov 26 10:41:44 EST 2025 Thu May 22 21:23:55 EDT 2025 Wed Feb 19 02:29:09 EST 2025 Sat Nov 29 01:49:40 EST 2025 Tue Nov 18 21:55:02 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c622t-397f02393b401b30e8cbf09ab39facbbb757df72f602bb2164a92858a148b97e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0000-0002-3533-2764 0000-0002-1331-4557 |
| OpenAccessLink | https://www.proquest.com/docview/2464362091?pq-origsite=%requestingapplication% |
| PMID | 33237959 |
| PQID | 2464362091 |
| PQPubID | 1436336 |
| PageCount | e0242630 |
| ParticipantIDs | plos_journals_2464362091 doaj_primary_oai_doaj_org_article_200f5eb17f104dcfbdbe33b39d5c83a4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7688145 proquest_miscellaneous_2464606744 proquest_journals_2464362091 gale_infotracmisc_A642812126 gale_infotracacademiconefile_A642812126 gale_incontextgauss_ISR_A642812126 gale_incontextgauss_IOV_A642812126 gale_healthsolutions_A642812126 pubmed_primary_33237959 crossref_citationtrail_10_1371_journal_pone_0242630 crossref_primary_10_1371_journal_pone_0242630 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-11-25 |
| PublicationDateYYYYMMDD | 2020-11-25 |
| PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2020 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | JM Racosta (pone.0242630.ref020) 2017; 55 J Beaute (pone.0242630.ref011) 2010; 160 A Martin (pone.0242630.ref012) 2013; 23 AF Mohamed (pone.0242630.ref039) 2012; 15 Z Liu (pone.0242630.ref010) 2005 B Perez-Escamilla (pone.0242630.ref034) 2015; 9 ME Younger (pone.0242630.ref038) 2015; 38 U Nicolay (pone.0242630.ref031) 2006; 26 MJ McBryde-Foster (pone.0242630.ref025) 2005; 23 B Hogy (pone.0242630.ref009) 2005; 6 IN van Schaik (pone.0242630.ref021) 2016; 17 VM Rasutis (pone.0242630.ref041) 2017; 40 H Abolhassani (pone.0242630.ref014) 2012; 32 C Lazzaro (pone.0242630.ref015) 2014; 35 pone.0242630.ref026 E. Sabate (pone.0242630.ref037) 2003 IN van Schaik (pone.0242630.ref004) 2019; 6 pone.0242630.ref027 TH Sach (pone.0242630.ref029) 2014 pone.0242630.ref002 pone.0242630.ref022 RD Hadden (pone.0242630.ref005) 2015; 8 pone.0242630.ref023 A Gardulf (pone.0242630.ref008) 1995; 345 G Le Masson (pone.0242630.ref040) 2018; 8 L Saldana (pone.0242630.ref030) 2014; 39 ET Ronckers (pone.0242630.ref028) 2006; 6 IN van Schaik (pone.0242630.ref003) 2018; 17 MP Lunn (pone.0242630.ref032) 2016; 21 C Perraudin (pone.0242630.ref013) 2016; 36 K Kuitwaard (pone.0242630.ref033) L Gentile (pone.0242630.ref007) 2020; 10 ME Kroese (pone.0242630.ref024) 2011 LH Markvardsen (pone.0242630.ref006) 2017; 378 B Vrijens (pone.0242630.ref001) 2012; 73 pone.0242630.ref018 A Bourdin (pone.0242630.ref019) 2015; 11 D Cocito (pone.0242630.ref016) 2012; 17 pone.0242630.ref035 S Martino (pone.0242630.ref036) 2015; 10 JA Allen (pone.0242630.ref017) 2019; 408 |
| References_xml | – ident: pone.0242630.ref026 – volume: 6 start-page: 24 issue: 1 year: 2005 ident: pone.0242630.ref009 article-title: Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance publication-title: Eur J Health Econ doi: 10.1007/s10198-004-0250-5 – volume: 35 start-page: 1023 issue: 7 year: 2014 ident: pone.0242630.ref015 article-title: Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis publication-title: Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology doi: 10.1007/s10072-014-1632-9 – volume: 38 start-page: 70 issue: 1 year: 2015 ident: pone.0242630.ref038 article-title: Subcutaneous immunoglobulin replacement therapy: ensuring success publication-title: Journal of infusion nursing: the official publication of the Infusion Nurses Society doi: 10.1097/NAN.0000000000000087 – volume: 10 start-page: 7910 issue: 1 year: 2020 ident: pone.0242630.ref007 article-title: Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years publication-title: Scientific reports doi: 10.1038/s41598-020-64699-6 – start-page: 38 year: 2011 ident: pone.0242630.ref024 article-title: Specialized rheumatology nurse substitutes for rheumatologists in the diagnostic process of fibromyalgia: a cost-consequence analysis and a randomized controlled trial publication-title: J Rheumatol – ident: pone.0242630.ref018 – volume: 345 start-page: 365 issue: 8946 year: 1995 ident: pone.0242630.ref008 article-title: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs publication-title: Lancet doi: 10.1016/S0140-6736(95)90346-1 – volume: 26 start-page: 65 issue: 1 year: 2006 ident: pone.0242630.ref031 article-title: Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home publication-title: Journal of clinical immunology doi: 10.1007/s10875-006-8905-x – volume: 9 start-page: 569 year: 2015 ident: pone.0242630.ref034 article-title: Identification of validated questionnaires to measure adherence to pharmacological antihypertensive treatments publication-title: Patient preference and adherence doi: 10.2147/PPA.S76139 – volume: 160 start-page: 240 issue: 2 year: 2010 ident: pone.0242630.ref011 article-title: Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies publication-title: Clinical and experimental immunology doi: 10.1111/j.1365-2249.2009.04079.x – volume: 378 start-page: 19 year: 2017 ident: pone.0242630.ref006 article-title: Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs publication-title: Journal of the Neurological Sciences doi: 10.1016/j.jns.2017.04.039 – volume: 6 start-page: 51 year: 2006 ident: pone.0242630.ref028 article-title: Costs of the 'Hartslag Limburg' community heart health intervention publication-title: BMC public health doi: 10.1186/1471-2458-6-51 – volume: 40 start-page: 305 issue: 5 year: 2017 ident: pone.0242630.ref041 article-title: High-Dose Subcutaneous Immunoglobulin in Patients With Multifocal Motor Neuropathy: A Nursing Perspective publication-title: Journal of infusion nursing: the official publication of the Infusion Nurses Society doi: 10.1097/NAN.0000000000000240 – volume: 23 start-page: 55 issue: 1 year: 2013 ident: pone.0242630.ref012 article-title: Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency publication-title: Transfusion medicine doi: 10.1111/j.1365-3148.2012.01201.x – volume: 17 start-page: 345 issue: 1 year: 2016 ident: pone.0242630.ref021 article-title: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial publication-title: Trials doi: 10.1186/s13063-016-1466-2 – ident: pone.0242630.ref023 – year: 2014 ident: pone.0242630.ref029 article-title: Applying micro-costing methods to estimate the costs of pharmacy interventions: an illustration using multi-professional clinical medication reviews in care homes for older people publication-title: The International journal of pharmacy practice – ident: pone.0242630.ref002 – volume: 17 start-page: 35 issue: 1 year: 2018 ident: pone.0242630.ref003 article-title: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: The Lancet Neurology doi: 10.1016/S1474-4422(17)30378-2 – volume: 6 start-page: e590 issue: 5 year: 2019 ident: pone.0242630.ref004 article-title: Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study publication-title: Neurology(R) neuroimmunology & neuroinflammation doi: 10.1212/NXI.0000000000000590 – ident: pone.0242630.ref027 – volume: 21 start-page: 33 issue: 1 year: 2016 ident: pone.0242630.ref032 article-title: A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. Journal of the peripheral nervous system publication-title: JPNS doi: 10.1111/jns.12158 – volume-title: Adherence to long-term therapies: evidence for action year: 2003 ident: pone.0242630.ref037 – volume: 10 start-page: 1 issue: 1 year: 2015 ident: pone.0242630.ref036 article-title: See One, Do One, Order One: a study protocol for cluster randomized controlled trial testing three strategies for implementing motivational interviewing on medical inpatient units publication-title: Implementation Science doi: 10.1186/s13012-015-0327-9 – volume: 36 start-page: 502 issue: 5 year: 2016 ident: pone.0242630.ref013 article-title: Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program publication-title: Journal of clinical immunology doi: 10.1007/s10875-016-0288-z – volume: 55 start-page: 802 issue: 6 year: 2017 ident: pone.0242630.ref020 article-title: Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis publication-title: Muscle & nerve doi: 10.1002/mus.25409 – volume: 39 start-page: 177 year: 2014 ident: pone.0242630.ref030 article-title: The Cost of Implementing New Strategies (COINS): A Method for Mapping Implementation Resources Using the Stages of Implementation Completion publication-title: Children and youth services review doi: 10.1016/j.childyouth.2013.10.006 – volume: 73 start-page: 691 issue: 5 year: 2012 ident: pone.0242630.ref001 article-title: A new taxonomy for describing and defining adherence to medications publication-title: British journal of clinical pharmacology doi: 10.1111/j.1365-2125.2012.04167.x – volume: 11 start-page: 831 issue: 469 year: 2015 ident: pone.0242630.ref019 article-title: Subcutaneous immunoglobulin and support program: what level of interest of patients? publication-title: Revue medicale suisse – volume: 408 start-page: 116497 year: 2019 ident: pone.0242630.ref017 article-title: Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG publication-title: J Neurol Sci doi: 10.1016/j.jns.2019.116497 – ident: pone.0242630.ref035 – volume: 8 start-page: e00923 issue: 2 year: 2018 ident: pone.0242630.ref040 article-title: Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis publication-title: Brain and behavior doi: 10.1002/brb3.923 – volume: 15 start-page: 1183 issue: 6 year: 2012 ident: pone.0242630.ref039 article-title: Patient and parent preferences for immunoglobulin treatments: a conjoint analysis publication-title: Journal of medical economics doi: 10.3111/13696998.2012.716804 – ident: pone.0242630.ref033 article-title: Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy publication-title: European journal of neurology – volume: 8 start-page: 14 issue: 1 year: 2015 ident: pone.0242630.ref005 article-title: Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction publication-title: Ther Adv Neurol Disord doi: 10.1177/1756285614563056 – year: 2005 ident: pone.0242630.ref010 – ident: pone.0242630.ref022 – volume: 32 start-page: 1180 issue: 6 year: 2012 ident: pone.0242630.ref014 article-title: Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis publication-title: Journal of clinical immunology doi: 10.1007/s10875-012-9720-1 – volume: 23 start-page: 31 issue: 1 year: 2005 ident: pone.0242630.ref025 article-title: Break-even analysis in a nurse-managed center publication-title: Nursing economic$. – volume: 17 start-page: 426 issue: 4 year: 2012 ident: pone.0242630.ref016 article-title: Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. Journal of the peripheral nervous system publication-title: JPNS doi: 10.1111/j.1529-8027.2012.00444.x |
| SSID | ssj0053866 |
| Score | 2.4246464 |
| Snippet | To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the... Purpose To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients... PurposeTo compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients... Purpose To compare the cost of two patient management strategies with similar efficacies for chronic inflammatory demyelinating polyneuropathy (CIDP) patients... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0242630 |
| SubjectTerms | Analysis Biology and Life Sciences Chemotherapy Cost analysis Cost-Benefit Analysis Costs Demyelinating diseases Demyelination Drug dosages Drug therapy Economic aspects Health care costs Health insurance Home Care Services - economics Hospitals Humans IgG antibody Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous - administration & dosage Immunoglobulins, Intravenous - economics Inflammation Infusions, Subcutaneous Insurance Intravenous administration Intravenous immunoglobulins Maintenance Medication Therapy Management - economics Medicine and Health Sciences Neurosciences Optimization Patients People and Places Pharmaceutical sciences Pharmacy Polyneuropathies Polyneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - economics Primary care Professionals Public health Social Sciences Switzerland Training |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELXQigMXRPlqoIBBSMAhJbGTOOG2ICq4FEQB9WbZjl1W2iarZhfUn8C_Zsb2Rg2qVA5c48kqmRmP521m3hDynKkGkmqmU9tiSw6cYSlcyVIjsqKtHGtMqfywCXF4WB8fN58vjPrCmrBADxwUB-A8cyUEFOEAOLTG6VZbzjVv2tLUXHkmUMh6tmAqxGDYxVUVG-W4yF9Hu-yv-s7uB5LybHIQeb7-MSrPVst-uCzl_Lty8sJRdHCL3Iw5JJ2HZ98h12x3m-zEXTrQl5FK-tUd8hunoKd4UrV02GizgVTQAtanC2wL6ZENBCvRKWSu1ASaXAouB15y6r--U-w2wY51hdXRdNUvzz0BJs4xPqeRk3V4Q-f06BdYkJp-ABy96Bansb2Tqkh6cpd8O3j_9d2HNA5fSE3F2DqFPMV5fjQNCEzzzNZGu6xRoHmnjNZalKJ1grkqY1ozQF1g47qsFeAr3QjL75FZB-reJbRxbaaYMHWmXNGoqsmx_ZfrvNHaCssSwreWkCYyk-OAjKX0n9sEIJSgWIn2k9F-CUnHu1aBmeMK-bdo5FEWebX9BfA2Gb1NXuVtCXmCLiJDk-oYHeQcYVwOaUCVkGdeArk1OizeOVGbYZAfP33_B6GjLxOhF1HI9aAOo2LDBLwTcnZNJPcmkhAhzGR5Fx16q5VBsgLy0IpBqgh3bp388uWn4zL-KBbkeTf1MoB9RQEquR_2xKhZzhnHEfYJEZPdMlH9dKVb_PDU5gB-67woH_wPWz0kNxj-OZLnKSv3yGx9trGPyHXzc70Yzh77ePEHqq11jg priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Library of Science (PLoS) Journals Open Access dbid: FPL link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Rb9QwDI7QjQckBGzAdjAgICTgoaNN2qbl7UCcQEJjYoD2ViVpApVu7Wm9Du0n8K-x01yh0ybgtXGq1rUTf439mZCnTOYQVDMVmBJLcmAPC-BKGGgRxmVqWa4T6ZpNiP397OgoP_gNFM-d4HMRvfQ63Vs2tdnrCcYBom8wnqaYwjU_-LBeecF309SXx102c7T9OJb-YS2eLBdNe1GgeT5f8o8NaH7zfx_9FrnhQ006621jk1wx9Ra53v-no3350RbZ9M7d0ueegfrFbfITm6cHuMGVtO2U7iCCNE3X0gqrSRokEcEEdgoBL9U9uy4FSwXjOnaH9hSLVLDQXWJSNV02izPHm4ntj8-op3JtX9EZPfwBH57qpgX4XdXVsa8KpdJzpdwhX-ZvP795F_ieDYFOGVsFEN5YR6umALgpHppMKxvmUvHcSq2UEokorWA2DZlSDMAamEaWZBJgmcqF4XfJpAZ17RCa2zKUTOgslDbOZZpHWDXMVZQrZYRhU8LXn7LQntAc-2osCndKJwDY9IouUP-F1_-UBMOsZU_o8Rf512glgyzScbsL8KEL793Yy9MmsOsJC-i21FaVynAO71wmOuMynpJHaGNFX9s6LCrFDNFfBNFDOiVPnARSctSY8_NNdm1bvP_49R-EDj-NhJ55IduAOrT0dRbwTkj1NZLcHUnCwqJHwzvoEWuttAWLIXxNGUSYMHPtJRcPPx6G8aaYx-fM1MkAZBYxqGS7d6pBs5wzjp3vp0SM3G2k-vFIXX13jOiAmbMoTu5d_sT3yTWGf0qiKGDJLpmsTjrzgFzVp6uqPXnolpFf0PB1ww priority: 102 providerName: Public Library of Science |
| Title | Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33237959 https://www.proquest.com/docview/2464362091 https://www.proquest.com/docview/2464606744 https://pubmed.ncbi.nlm.nih.gov/PMC7688145 https://doaj.org/article/200f5eb17f104dcfbdbe33b39d5c83a4 http://dx.doi.org/10.1371/journal.pone.0242630 |
| Volume | 15 |
| WOSCitedRecordID | wos000593887000057&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agriculture Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYxwMSAjY-VhjFICTgIV3ifDjhBbXTKqaxEnVsKrxEtpOMSl1Smha0P4H_mjvHLQRNgMTLPcSXqnF-d-dzfL8j5DkTESyqmbSyFEtyIIZZcMW2FLe9NMhZpHyhm03w4TAcj6PYbLhV5ljlyidqR52WCvfI95gHsTNgEN7ezL5Y2DUKv66aFhobZBNZEtAwY__TyhODLQeBKZdzubNn3k53VhZZt6YqtxvhSLP2r31zazYtq6sWnr-fn_wlIA1u_--j3CG3zFKU9mrsbJFrWbFNbtb7eLQuT9omW8b4K_rSMFS_uku-Y3N1CwNgSqulVEtYYWblsqITrDYpkWQED7hTWBBTVbPvUkAygO9Cf9SnWMSChfACD13TWTm91Lya2B75khqq1-o17dGTbwAMqsoK0vNJMbkwVaNUGC6Ve-R0cPBh_61lejpYKmBsYcHyJ9e0axISO-naWahkbkdCulEulJSS-zzNOcsDm0nJIJkD6IR-KCBtkxHP3PukVcD72yE0ylNbMK5CW-ReJILIwapiVzqRlBnPWJu4q1ebKEN4jn03pon-isch8aknOkFAJAYQbWKt75rVhB9_0e8jata6SNetL5Tz88RYP_b6zH2IijyH7DdVuUxl5rrwzKmvQld4bfIEMZfUta9rp5P0MDsEZLOgTZ5pDaTsKPBM0LlYVlVy-P7sH5RORg2lF0YpL2E6lDB1GPBMSAXW0NxtaILjUY3hHbSQ1axUyU9cw50r5F89_HQ9jD-K5_w0TLUOpNTcgyl5UBvZemZdl7k88qM24Q3za0x9c6SYfNaM6ZBTh47nP_zz33pEbjDcTXEci_m7pLWYL7PH5Lr6uphU8w7Z4KMzlGOuZQgy3Hc6ZLN_MIxHHb2bA3IQvwN51O-CPLaPUPJYy5OOdk9wR3x4HH_8AXPTlB0 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELdGQQIJARsfKwxmEAh4yJbYSZwgIVQ-plUbY2ID9S3YTjIqdU1pWqb-Cfwz_I3cOU4gaAJe9sBrfImSy33ad78j5CGTMQTVTDlZii054MMcuOI6Wrh-GuYs1oE0wybE3l40GMT7S-R73QuDZZW1TTSGOi007pFvMh98Z8jAvb2YfHFwahSertYjNCqx2MkWJ5Cylc_7r-H_PmJs683hq23HThVwdMjYzAEHnBvgLwWpheJuFmmVu7FUPM6lVkqJQKS5YHnoMqUYpBPw8lEQSUgcVCwyDs89R86DHRdYQiYGTYIHtiMMbXseF96mlYaNSTHONipodLfl_syUgMYXdCajojwt0P29XvMXB7h19X9j3TVyxYbatFfpxjJZysYr5HK1T0mr9qsVsmyNW0mfWATup9fJNxwe76CDT2k5V3oOEXRWzEs6xG6aAkFUsICfQsBPdYUuTEFTQbmOTdECxSYdbPSXWFROJ8VoYXBDcfzzgloo2_IZ7dGDExB8qoty5iDIy7HtiqXSYsXcIB_OhEU3SWcM8rJKaJynrmRCR67M_ViGsYdd01x5sVKZyFiX8FqUEm0B3XGuyCgxp5QCEruK0QkKYGIFsEuc5q5JBWjyF_qXKKUNLcKRmwvF9Cix1g1nmeYBeH2RQ3af6lylKuMcvjkNdMSl3yXrKONJ1dvbGNWkh9mvB9FT2CUPDAVCkoyx5ulIzssy6b_7-A9EB-9bRI8tUV4AO7S0fSbwTQh11qJca1GCYdWt5VXUyJorZfJTj-DOWtNOX77fLONDsY7RiKmhCSFA9IEltyqlbjjLOeMiDuIuES11b7G-vTIefjaI8CKMIs8Pbv_5tdbJxe3Dt7vJbn9v5w65xHDnyPMcFqyRzmw6z-6SC_rrbFhO7xmzRsmnszYGPwA7U-P0 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELdGQQgJARsfKwxmEAh4yJo4H06QECqMimqoVAzQxEuwnXhU6prStEz9E_iX-Ou4c5xC0AS87IHX-BLFl_t07n5HyH0mEgiqmXTyDFtywIc5cMV1FHeDLNIsUaEwwyb4YBAfHCTDNfK97oXBssraJhpDnRUKz8g7LADfGTFwbx1tyyKGu71n0y8OTpDCP631OI1KRPby5TGkb-XT_i586weM9V6-e_HKsRMGHBUxNnfAGWsDAiYhzZC-m8dKajcR0k-0UFJKHvJMc6Yjl0nJILWAjcRhLCCJkAnPfXjuGXKWQ46Jid8w_Fh7AbAjUWRb9Xzudaxk7EyLSb5TwaS7DVdoJgas_EJrOi7Kk4Le32s3f3GGvcv_MxuvkEs2BKfdSmfWyVo-2SAXq_NLWrVlbZB1a_RK-sgicz--Sr7hUHkHHX9Gy4VUC4is82JR0hF22RQIroKF_RQSAaoq1GEKGgxKd2SKGSg27yAAgMBiczotxkuDJ4pjoZfUQtyWT2iX7h-DQlBVlHMHwV-ObLcsFRZD5hp5fyosuk5aE5CdTUITnbmCcRW7QgeJiBIPu6l96SVS5jxnbeLXYpUqC_SO80bGqfl7ySHhqxidojCmVhjbxFndNa2ATv5C_xwldkWLMOXmQjE7TK3VwxmnOoRogGvI-jOlZSZz34c9Z6GKfRG0yTbKe1r1_K6MbdrFrNiDqCpqk3uGAqFKJiith2JRlmn_zYd_INp_2yB6aIl0AexQwvafwJ4QAq1BudWgBIOrGsubqJ01V8r0p07BnbXWnbx8d7WMD8X6RiOmhiaCwDEAltyoFHzFWd9nPk_CpE14Q_UbrG-uTEafDVI8j-LYC8Kbf36tbXIebED6uj_Yu0UuMDxQ8jyHhVukNZ8t8tvknPo6H5WzO8bCUfLptG3BDy2k7Oc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Home-based+subcutaneous+immunoglobulin+for+chronic+inflammatory+demyelinating+polyneuropathy+patients%3A+A+Swiss+cost-minimization+analysis&rft.jtitle=PloS+one&rft.au=Perraudin%2C+Cl%C3%A9mence&rft.au=Bourdin%2C+Aline&rft.au=Vicino%2C+Alex&rft.au=Kuntzer%2C+Thierry&rft.date=2020-11-25&rft.eissn=1932-6203&rft.volume=15&rft.issue=11&rft.spage=e0242630&rft_id=info:doi/10.1371%2Fjournal.pone.0242630&rft_id=info%3Apmid%2F33237959&rft.externalDocID=33237959 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |